1229005-35-9

Usage

Uses

Used in Pharmaceutical Industry:
Tatariid A is used as a potential therapeutic agent for its anti-inflammatory properties, offering a natural alternative for managing inflammation-related conditions.
Used in Oncology:
Tatariid A is used as an anti-tumor agent, targeting the growth of certain cancer cell lines and showing promise in laboratory studies for its potential role in cancer treatment.
Used in Antifungal Applications:
Tatariid A is used as an anti-fungal agent, leveraging its natural properties to combat fungal infections.
Used in Drug Development Research:
Tatariid A is used as a subject of research for drug development, with ongoing studies investigating its mechanisms of action and exploring its potential for therapeutic use in various medical fields.

Upstream product

• 22973-79-1 2-(2,4,5-trimethoxyphenyl)acetaldehyde 
• 3904-18-5 isoacoramone 
• 29652-82-2 1-(2,4,5-Trimethoxyphenyl)propan-1-ol 
• 1422453-73-3 (R)-2-(tert-butyldimethylsilyloxy)-1-(2,4,5-trimethoxyphenyl)propan-1-one 

Relevant academic research and scientific papers

Asymmetric Oxidation of Enol Derivatives to α-Alkoxy Carbonyls Using Iminium Salt Catalysts: A Synthetic and Computational Study

We report herein the first examples of asymmetric oxidation of enol ether and ester substrates using iminium salt organocatalysis, affording moderate to excellent enantioselectivities of up to 98% ee for tetralone-derived substrates in the α-hydroxyketone products. A comprehensive density functional theory study was undertaken to interpret the competing diastereoisomeric transition states in this example in order to identify the origins of enantioselectivity. The calculations, performed at the B3LYP/6-31G(D) level of theory, gave good agreement with the experimental results, in terms of the magnitude of the effects under the specified reaction conditions, and in terms of the preferential formation of the (R)-enantiomer. Just one of the 30 characterized transition states dominates the enantioselectivity, which is attributed to the adoption of an orientation relative to stereochemical features of the chiral controlling element that combines a CH interaction between a CH2 group in the substrate and one of the aromatic rings of the biaryl section of the chiral auxiliary with a good alignment of the acetoxy group with the other biaryl ring, and places the smallest substituent on the alkene (a hydrogen atom) in the most sterically hindered position.

Syntheses of (-)-Tatarinoid A, (±)-Tatarinoid B, and (-)-Tatarinoid C

The syntheses of (-)-Tatarinoid A, (±)-Tatarinoid B, and (-)-Tatarinoid C in one to three steps are described herein. (-)-Tatarinoid A and (-)-Tatarinoid C are both constructed in three steps from 1-bromo-2,4,5-trimethoxybenzene in overall yields of 63% and 74%, respectively. The addition of (1-methoxyethyl)triphenylphosphonium ylide to 2,4,5-trimethoxybenzaldehyde provides (±)-Tatarinoid B in one step in 97% yield.